<DOC>
	<DOCNO>NCT02528786</DOCNO>
	<brief_summary>The purpose study obtain blood sample 14 subject previously receive namilumab previous study M1-1188-002-EM ( PRIORA , [ NCT01317797 ] ) correlate genetic marker clinical outcome .</brief_summary>
	<brief_title>Blood Sample Collection Study Pharmacogenomic Characterization Participants That Previously Received Namilumab M1-1188-002-EM ( PRIORA , NCT01317797 ) Study .</brief_title>
	<detailed_description>Participants receive treatment namilumab previous study M1-1188-002-EM ( PRIORA [ NCT01317797 ] ) two whole blood sample ( 3 mL ) collect correlate genetic marker namilumab treatment response determine previous study . The study enroll approximately 14 participant receive namilumab previous study . â€¢ No intervention administer study . This trial conduct Bulgaria , Spain The Netherlands . The overall time participate study 1 day .</detailed_description>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>1 . The participant ( , applicable , participant 's legally acceptable representative ) voluntarily sign date write , informed consent form require privacy authorization prior initiation study procedure . 1 . Did receive namilumab PRIORA study ( A phase Ib doubleblind , placebo control , randomize , doseescalating study ) . 2 . Participants without response time point record 4week last dose namilumab beyond time point 3 . Participants exclude posthoc analysis due protocol violation previous PRIORA study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>